Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally.  Avistone has an extensive pipeline of targeted therapies including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage.  The Company’s lead asset is PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity, including aberrant activity observed with METexon14 skipping (genetic) alterations in NSCLC tumors and in other solid tumors.  The company's second clinical asset is PLB1004, a potent inhibitor of EGFR tyrosine kinases (TKI), including aberrant activity observed with EGFR exon20 insertion (genetic) mutations in NSCLC tumors.  

Avistone Biotechnology Co., Inc

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

Incyte

Syndax is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment.

Syndax

Leap Therapeutics is a biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer treatment.

Leap Therapeutics

Eidos Therapeutics is a biopharmaceutical company dedicated to developing novel therapies for rare and life-threatening diseases.

Eidos Therapeutics

Oncora Medical is a healthcare technology company that provides precision medicine solutions for cancer care.

Oncora Medical

Avistone is a biotechnology company that develops innovative drugs. The company's core team consists of experienced professionals with expertise in early drug development, clinical study, industrial production, and commercial development.

Avistone

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	May 3, 2024 1:33 PM	8c993918
public peers	general	May 3, 2024 1:33 PM	50eec722
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 3, 2024 1:33 PM	78f21395
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 3, 2024 1:33 PM	6aea0657
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 3, 2024 1:33 PM	10031d7a
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:AVISTONEBIO

Avistone